Metabolic syndrome-related hepatocellular carcinoma treated by volumetric modulated arc therapy

J. Klein, L. A. Dawson, T. H. Tran, O. Adeyi, T. Purdie, M. Sherman, A. Brade

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality, and its incidence is increasing in developed countries. Risk factors include cirrhosis from viral hepatitis or alcohol abuse. Metabolic syndrome is a newly recognized, but important, risk factor that is likely contributing to the increased incidence of HCC. Surgery is the therapy of choice for HCC, but local therapies are often contraindicated, usually because of advanced disease or comorbid conditions such as cardiac disease (which is associated with metabolic syndrome). Current radiation therapy techniques such as stereotactic body radiotherapy allow for treatment plans that highly conform to the target and provide excellent sparing of normal structures. Radiation therapy is emerging as a viable option in patients not eligible for surgery or other locoregional therapies. Here, we report a case of a large hcc presenting in a patient with metabolic syndrome without significant alcohol history or biochemical liver dysfunction. The patient was not a candidate for locoregional therapies because of cardiac and renal comorbidities typical of patients experiencing the long-term sequelae of metabolic syndrome. Treatment using an arc-based volumetric-modulated arc therapy technique allowed for the highest dose of radiation to be delivered to the tumour while the peripheral radiation dose was minimized. A complete local response was confirmed by computed tomography imaging 21 months after treatment completion.

Original languageEnglish (US)
Pages (from-to)e340-e344
JournalCurrent Oncology
Issue number2
StatePublished - 2014
Externally publishedYes


  • Hepatocellular carcinoma
  • IMRT
  • Liver cancer
  • Metabolic syndrome
  • Radiotherapy
  • SBRT
  • VMAT


Dive into the research topics of 'Metabolic syndrome-related hepatocellular carcinoma treated by volumetric modulated arc therapy'. Together they form a unique fingerprint.

Cite this